CYP inhibition

CYP inhibition is what happens when one drug jams the body's metabolic machinery so a second drug cannot be broken down on schedule. Imagine two cars trying to use the same narrow toll lane: if the first car stalls in the booth, everything behind it piles up. When a CYP enzyme is blocked, its substrate drugs accumulate to higher-than-intended levels.

Inhibition comes in forms that matter clinically. Reversible inhibition — competitive or otherwise — happens when an inhibitor simply occupies the enzyme and lets go again, so its effect tracks the inhibitor's own concentration. Mechanism-based (time-dependent) inhibition is more troubling: the enzyme converts the inhibitor into a species that permanently disables it, so activity returns only as the body synthesizes new enzyme, prolonging the interaction.

Because raising a co-medication's exposure can push it into toxic territory, screening candidates for CYP inhibition is a routine safety step. Chemists measure the inhibition constant or IC50 against the major isoforms, and a potent inhibitor of an enzyme like CYP3A4 is treated as a liability that may need to be designed out or carefully managed with dosing warnings.